Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Observer-blind, First-in-human Study to Describe the Safety, Reactogenicity and Immunogenicity of SCB-1022 and SCB-1033 in Healthy Older Adults Aged 60-85 Years
Conditions
Interventions
SCB-1019T
SCB-1022
+1 more
Locations
1
Australia
Fusion Clinical Research
Adelaide, Southern Australia, Australia
Start Date
June 18, 2025
Primary Completion Date
March 3, 2026
Completion Date
June 30, 2026
Last Updated
August 8, 2025
Lead Sponsor
Clover Biopharmaceuticals AUS Pty
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions